Impact of glucocorticoids on insulin resistance in the critically ill by Pretty, C.G. et al.
1 
 
Impact of glucocorticoids on insulin resistance in the critically ill 
Authors: 
Christopher Pretty  
Department of Mechanical Engineering  
University of Canterbury,  
Private Bag 4800  
Christchurch 8140 
New Zealand  
Email: cgp19@student.canterbury.ac.nz 
Ph: +64 3 364 2987 ext. 7486 
 
Prof J. Geoffrey Chase,  
Department of Mechanical Engineering  
University of Canterbury,  
Private Bag 4800  
Christchurch 8140 
New Zealand  
Email: geoff.chase@canterbury.ac.nz 
 
Jessica Lin 
Department of Medicine 
University of Otago Christchurch 
PO Box 4345 
Christchurch 8140 
New Zealand 
 
Geoffrey M Shaw 
Department of Intensive Care 
Christchurch Hospital 
Private Bag 4710 
Christchurch 8140 
New Zealand 
 
Aaron Le Compte 
Department of Mechanical Engineering  
University of Canterbury,  
Private Bag 4800  
Christchurch 8140 
New Zealand  
 
 
2 
 
 
 
Normy Razak 
Department of Mechanical Engineering  
University of Canterbury,  
Private Bag 4800  
Christchurch 8140 
New Zealand  
 
Jacquelyn D Parente 
Department of Mechanical Engineering  
University of Canterbury,  
Private Bag 4800  
Christchurch 8140 
New Zealand  
 
Financial Support: New Zealand Tertiary Education Commission. 
Keywords: critical care, hyperglycaemia, insulin resistance, glucocorticoids, mathematical model, 
algorithms 
3 
 
Abstract 
Glucocorticoids (GCs) have been shown to reduce insulin sensitivity in healthy individuals. Widely 
used in critical care to treat a variety of inflammatory and allergic disorders, they may inadvertently 
exacerbate stress-hyperglycaemia. This research uses model-based methods to quantify the reduction 
of insulin sensitivity from GCs in critically ill patients, and thus their impact on glycaemic control. A 
clinically validated model-based measure of insulin sensitivity (SI) was used to quantify changes 
between two matched cohorts of 40 intensive care unit (ICU) patients who received GCs and a control 
cohort who did not. All patients were admitted to the Christchurch hospital ICU between 2005 and 
2007 and spent at least 24 hours on the SPRINT glycaemic control protocol. 
 
A 31% reduction in whole-cohort median insulin sensitivity was seen between the control cohort and 
patients receiving glucocorticoids with a median dose equivalent to 200mg/day of hydrocortisone per 
patient. Comparing percentile-patients as a surrogate for matched patients, reductions in median 
insulin sensitivity of 20, 25, and 21% were observed for the 25th, 50th and 75th-percentile patients. All 
these cohort and per-patient reductions are less than or equivalent to the 30-62% reductions 
reported in healthy subjects especially when considering the fact that the GC doses in this study are 
1.3-4 times larger than those in studies of healthy subjects. This reduced suppression of insulin 
sensitivity in critically ill patients could be a result of saturation due to already increased levels of 
catecholamines and cortisol common in critically illness. Virtual trial simulation showed that 
reductions in insulin sensitivity of 20-30% associated with glucocorticoid treatment in the ICU have 
limited impact on glycaemic control levels within the context of the SPRINT protocol. 
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Introduction 
Hyperglycaemia is prevalent in critical care [1-5]. Increased secretion of counter-regulatory hormones 
stimulates endogenous glucose production and reduces effective insulin sensitivity [3-4, 6]. Studies by 
van den Berghe et al. [5, 7], Krinsley [8] and Chase et al. [2] have shown that tight glucose control can 
reduce ICU mortality by 18-45%. Glucocorticoids are used in critical care to treat a variety of 
inflammatory and allergic disorders, but may exacerbate stress-hyperglycaemia through their side 
effect of reducing insulin sensitivity and may thus indirectly impact clinical outcome. 
 
Studies have shown that glucocorticoids (GCs) increase insulin resistance (reduce insulin sensitivity) in 
healthy individuals [9-13]. However, there is a lack of data about whether this effect is equally valid, 
or equally large, for critically ill patients. Insulin resistance, defined by relatively low insulin-mediated 
glucose disposal, is common and can be extreme in critically ill patients, which makes tight glycaemic 
control (TGC) in intensive care unit (ICU) patients difficult. Treatment with GCs may therefore make 
this task even harder if they yield significant (further) reductions of insulin sensitivity. Model-based 
methods can readily quantify changes in the insulin resistance of critically ill patients where typical 
methods of assessing this metric may be difficult to apply. 
 
Several studies have reported 30-62% decreases in insulin sensitivity of healthy subjects after short-
term administration of dexamethasone (2 or 6 mg/d) [9-12]. Pagano et al. [13] documented a similar 
change with prednisone (15 mg/d). The mechanisms and pathways underlying these dramatic 
reductions in insulin sensitivity are not yet fully understood. Metabolic adaptations, including 
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enhanced endogenous glucose production (EGP), increased plasma insulin concentrations, and 
reduced whole-body glucose disposal were also reported in these studies. 
 
The primary hypothesis of this research is that insulin sensitivity is reduced by glucocorticoids in 
critically ill patients, but potentially to a lesser extent than in healthy individuals. Therefore, the aim 
of this research is to use model-based methods to quantify the effect of glucocorticoid therapy on 
insulin sensitivity of ICU patients and its impact on the resulting TGC interventions. These results will, 
for matched cohorts, enable assessment of whether GC therapy in the critically ill is detrimental to 
achieving tight glycaemic control, and thus potentially to patient outcome. 
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Materials and Methods 
Subjects 
This research was conducted as a retrospective study using records from 80 patients admitted to the 
Christchurch ICU between 2005 and 2007. A model-based measure of insulin sensitivity (SI) was used 
to quantify changes between two matched, critically ill cohorts. 
 
A cohort of 40 patients, who each spent 24 hours or more on the SPRINT glycaemic control protocol 
[2] and received glucocorticoid therapy during this time, was selected from the available records. 
These patients had received treatment with one or more of the steroids listed in Table 1. The per-
patient median steroid dose was equivalent to 200mg/d of hydrocortisone [14-16]. Patients were 
excluded if they received β-blockers or ACE-inhibitors, as these therapeutics can affect glucose 
metabolism and insulin sensitivity in an opposing fashion [17-19].  
 
In cases where patients did not receive steroid therapy for the entire time they were on SPRINT, 
insulin sensitivity was considered to be affected by the drug for one effective biological half-life 
following the last dose. This period ensured that any effects of the exogenous glucocorticoids on 
insulin sensitivity had not reduced so far as to be undetectable or swamped by elevated levels of 
circulating endogenous cortisol, which is also common in critically ill patients [20]. However, this short 
period precludes useful comparison between on- and off-steroid insulin sensitivities within the cohort 
as exogenous glucocorticoids may have a significant effect on SI in some patients for longer than one 
half-life. 
7 
 
 
Relative potencies and biological half-lives of the glucocorticoids were based on data for anti-
inflammatory effects as these closely parallel the effects on glucose metabolism [16]. Table 1 lists the 
potencies and half-lives used in analysis of the steroids for this research. 
 
Table 1. Glucocorticoids and their properties used in this study [14-16].  
 
 
A control cohort of 40 patients, who did not receive any glucocorticoid, β-blocker or ACE-inhibitor 
therapy, was also selected from patients on the SPRINT protocol. Patients were selected so that the 
overall cohort parameters (age, sex, outcome, severity of illness), shown in Table 2, matched the 
steroid cohort as closely as possible. While the cohorts are matched for overall glycaemic levels, the 
control cohort had more time in the 4.0-7.0mmol/L glycaemia band than the steroid cohort. 
 
The SPRINT protocol is a simple, lookup-table system derived from a model-based controller that 
modulates insulin and nutritional inputs. The protocol titrates insulin doses and nutrition rates to 
patient-specific insulin sensitivity for tight glycaemic control [2, 21-22]. SPRINT has been used in the 
Christchurch ICU since August 2005 on more than 1,000 patients. The requirement for patients in this 
Compound Relative anti-inflammatory potency
Duration of action / 
Effective biological half-
life (hrs)
Hydrocortisone 1 10
Prednisone 4 24
Prednisolone 4 24
Methyl-Prednisolone 5 24
Dexamethasone 25 45
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study to be on the SPRINT protocol ensures they have regular, consistent and accurate records of 
blood glucose level, and insulin and nutrition administration. It also ensures the two cohorts have 
clinically very similar levels of glycaemic control, as this study focuses on the potential impact of 
glucocorticoids on TGC. The use of these patient records falls under existing ethics approval granted 
by the Upper South Regional Ethics Committee, New Zealand. 
 
Table 2. Comparison of the steroid and control cohorts. Data are not necessarily normally distributed 
and are thus shown as median [interquartile range] where appropriate. 
  
ap-values calculated with two-sided Fisher’s exact test. bp-values calculated with Mann-Whitney U test. 
 
Control 
Cohort
Steroid 
Cohort
N 40 40
Mortality (%) 25 32.5 p = 0.62a
Operative/Non-operative 12/28 11/29 p = 1.00a
Gender M/F 23/17 20/20 p = 0.65a
65.5 61.5
[51-73] [52-74]
20.0 22.5
[18-27] [18-28]
38.3 39.7
[23-64] [23-62]
102.5 102.0
[42-155] [66-153]
5.7 5.9
[5.3-6.1] '[5.3-6.3]
Measurements in BG 
band [4.0-7.0 mmol/L] (%) 82 76 p < 0.001
a
Total time on SPRINT 
(hrs) 5259 4914
Total time on Steroids 
(hrs) 0 3489
0 200
[80-200]
p = 0.95b
Equivalent daily dose of 
hydrocortisone (mg)
p = 0.63b
APACHE II Risk of death 
(%)
Patient time on SPRINT 
(hrs)
AGE (yrs) p = 0.74b
Patient median blood 
glucose (mmol/l) p = 0.49
b
p = 0.83bAPACHE II Score
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Model-Based Insulin Sensitivity 
This study used a model based on the clinically validated glucose-insulin models of Le Compte et al. 
[23] and Lotz et al. [24]. The model-based insulin sensitivity has been shown to correlate well with the 
insulin sensitivity index (ISI) determined by the gold-standard hyperinsulinaemic-euglycaemic clamp 
(r > 0.90) [24]. Implementing this model in Matlab™ (Mathworks, Natick MA) with ICU patient data, an 
SI value was identified every hour for every patient while on the SPRINT protocol. In this way, 4,914 
and 5,259 SI values were obtained for the steroid and control cohorts respectively. 
 
The glucose-insulin system model is defined below and the model parameters, rates and constants 
are described in Tables 3 and 4:  
?̇?(𝑡) = −𝑝𝐺𝐺(𝑡) − 𝑆𝐼(𝑡)𝐺(𝑡) 𝑄(𝑡)1+𝛼𝐺𝑄(𝑡) + 𝑃(𝑡)+𝐸𝐺𝑃−𝐶𝑁𝑆𝑉𝐺       (1) 
?̇?(𝑡) = 𝑛𝐼�𝐼(𝑡) − 𝑄(𝑡)� − 𝑛𝐶 𝑄(𝑡)1+𝛼𝐺𝑄(𝑡)        (2) 
𝐼(̇𝑡) = −𝑛𝐾𝐼(𝑡) − 𝑛𝐿 𝐼(𝑡)1+𝛼𝐼𝐼(𝑡) − 𝑛𝐼�𝐼(𝑡) − 𝑄(𝑡)� + 𝑢𝑒𝑥(𝑡)𝑉𝐼 + (1 − 𝑥𝐿) 𝑢𝑒𝑛(𝑡)𝑉𝐼    (3) 
𝑃(𝑡) = min(𝑑2𝑃2,𝑃𝑚𝑎𝑥) + 𝑃𝑁(𝑡)         (4) 
?̇?2(𝑡) = −min(𝑑2𝑃2(𝑡),𝑃𝑚𝑎𝑥) + 𝑑1𝑃1(𝑡)        (5) 
?̇?1(𝑡) = −𝑑1𝑃1(𝑡) + 𝐷(𝑡)          (6) 
𝑢𝑒𝑛(𝑡) = 𝑘1𝑒−𝐼(𝑡)𝑘2𝑘3   when C-peptide data is not available as in [24].    (7) 
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Table 3 Glucose-insulin system model time varying parameters. 
  
Table 4. Glucose-insulin system model population constant parameters. 
 
Parameter Units Parameter description
SI(t) L/mU.min Model-fitted insulin sensitivity
G(t) mmol/L Plasma glucose concentration 
I(t) mU/L Plasma insulin concentration
Q(t) mU/L Interstitial insulin concentration
uex(t) mU/min Exogenous insulin input
uen(t) mU/min Endogenous insulin production
D(t) mmol/min Enteral glucose nutrition
PN(t) mmol/min Parenteral glucose nutrition
P(t) mmol/min Glucose flux from gut to plasma
Parameter Value Parameter description
pG 0.006 min
-1 Non-insulin mediated glucose removal rate
EGPb 1.16 mmol/min Basal endongenous glucose production rate
CNS 0.3 mmol/min Central nervous system glucose uptake
VG 13.3 L Glucose volume of distribution
VI 3.15 L Insulin volume of distribution
αI 1.7x10-3 L/mU Saturation parameter for hepatic insulin clearance
αG 0.0154 L/mU Saturation parameter for insulin mediated glucose uptake
nI 0.003 min
-1 Plasma-interstitium insulin diffusion rate
nC 0.003 min
-1 Receptor bound insulin degradation rate
nK 0.0542 min
-1 Renal insulin clearance rate
nL 0.1578 min
-1 Hepatic insulin clearance rate
d1 -log(0.5)/20 min
-1 Glucose flux from stomach to gut
d2 -log(0.5)/100 min
-1 Glucose flux from gut to plasma
Pmax 6.11 mmol/min Maximum glucose flux from gut to plasma
xL 0.67 First pass hepatic insulin clearance
k1 45.7 mU/min Basal endongenous insulin production rate
k2 1.5 Endogenous insulin suppression parameter 2
k3 1000 Endogenous insulin suppression parameter 3
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This model combines aspects from both Le Compte et al. [23] and Lotz et al. [24]. The glucose 
dynamics (Equation (1)) are very similar to those of Le Compte et al. [23] where G represents the 
absolute blood glucose value and there are separate endogenous glucose production (EGP) and 
central nervous system uptake (CNS) terms. With G representing absolute glycaemic level rather than 
the level above a basal set point as in Lotz et al. [24], the model is more applicable for clinical use. 
Experience with a large range of ICU patients has shown that it is difficult to identify a basal set point 
glucose level (GE) in a clinical setting. The benefit of identifying GE is limited as it only affects the first 
term of (1), which does not have a large overall contribution owing to the small value of pG. 
 
The insulin kinetics of Equations (2)-(3) were taken from the model of Lotz et al. [24] and have explicit 
terms for the major insulin clearance and diffusion pathways. Adding to the model of Lotz et al. [24] is 
the saturation term for receptor-bound insulin degradation in Equation (2). This term comes from the 
realisation that both the action and degradation of insulin bound to cellular receptors is saturable 
[25]. Equation (7) defines an endogenous insulin secretion term similar to Le Compte et al. [23] but 
suppressed by plasma insulin level rather than exogenous insulin delivery rate.  
 
New to this formulation of the glucose insulin system model is the two compartment nutritional input 
model described by Equations (4)-(6). This model is based on the work of Worthington et al. [26] and 
Wong et al. [27] and ensures mass conservation of enterally delivered glucose.  
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Analysis 
Non-parametric statistics (median, interquartile range) were used to define the location and spread of 
insulin sensitivity and blood glucose as typical distributions are asymmetric and skewed, rendering 
Gaussian statistics unsuitable [28]. Baseline variables were compared using the Mann-Whitney U test 
for continuous data or two-sided Fisher’s exact test for categorical data. Insulin sensitivity values were 
compared using cumulative distribution functions (CDFs) and the Mann-Whitney U test for statistical 
significance. CDFs show the entire shape of the distribution, which is particularly useful for skewed 
data sets [29]. P–values of less than 0.05 were considered significant. 
 
Overall cohort comparisons of insulin sensitivity were possible with the matched cohorts. However, as 
individual patients cannot be explicitly matched, percentile patients are used as a surrogate for 
explicit per-patient analyses. Comparisons were made between equivalent percentile patients from 
each cohort. A box plot was used to clearly reveal the differences in SI between percentile patients at 
all likelihood values, rather than just the median. Positive values for the differences indicate lower 
insulin sensitivity for the steroid percentile patients compared to the controls. 
 
A range of percentile patients from each cohort were identified using the CDFs of all the individual 
patients of each cohort. At each cumulative likelihood, a given percentile value of insulin sensitivity 
was determined across all patients and this value formed part of the percentile patient’s CDF. An 
example is illustrated in Figure 1 at three likelihood values for the 50th-percentile, or median patient. 
A high level of parallelism between individual CDFs (low level of crossover) ensures these percentile 
patient CDF results are representative of realistic patient responses, if not guaranteed to be a specific 
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individual patient. The example in Figure 1 (steroid cohort CDFs) shows there is little difference 
between the median patient and any of the surrounding, individual patient CDFs. 
 
Figure 1. Percentile patient analysis – determining the theoretical “median patient”. The distributions 
of per-patient insulin sensitivity along the x-axis at cumulative likelihoods of 0.2, 0.5 and 0.8 are 
shown. The median of these three distributions contribute three data points to the CDF of the 
“median patient”. This process is repeated for all cumulative likelihoods in the range [0,1] and can be 
performed for other percentile patients besides the median patient shown.  
 
Thus, the following comparisons of SI are made: 
 Overall cohort - to determine the overall shift in SI
 25
 distributions between cohorts. 
th, 50th and 75th percentile patients - to investigate differences in SI
 Difference in S
 on a per-patient basis. 
I (∆SI) at all likelihoods over the 5-95
th
 
 percentile patients - to examine any trends 
in the changes to the insulin sensitivity distributions. 
14 
 
Simulation Analysis 
To quantify any clinically relevant effect of glucocorticoid-mediated changes in insulin sensitivity on 
blood glucose control and interventions under the SPRINT protocol, clinically validated virtual patient 
simulations [30] were conducted on the two study cohorts. The simulations used the glucose-insulin 
model with the SPRINT protocol controller and the identified insulin sensitivity profiles for each 
patient to generate a time course of expected glucose levels. These in-silico virtual patients have been 
reported to accurately represent clinical results [21, 30-31]. 
 
Increasing the insulin sensitivities of steroid cohort patients in simulation by 25 and 43% for the 
periods they received steroids effectively reverses glucocorticoid-mediated reductions to SI of 20 to 
30% respectively. Similarly, reducing the SI of the control cohort by 20 and 30% for 70% of the time 
they spent on SPRINT simulated the effects of steroid administration on these control cohort patients 
for the proportion of their stay that is comparable to the steroids cohort. This simulation allows the 
impact of GCs on TGC and its interventions to be determined. 
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Results 
Overall cohort analysis 
Insulin sensitivity in patients receiving glucocorticoids was lower than control patients in an overall 
cohort comparison. Median insulin sensitivity was reduced 31% from 3.49x10-4 to 2.40x10-4 L/mU.min 
(p < 0.001). Figure 2 shows the CDFs for both cohorts. There is a clear separation between the control 
cohort and the steroid cohort (while receiving steroids) distributions at all likelihood values.   
 
Figure 2. CDFs of insulin sensitivity for control and steroid cohorts. The steroid cohort has lower 
insulin sensitivity whilst on steroids compared to the control cohort at almost all likelihood values. 
 
The CDF of insulin sensitivity of the steroid cohort is also shown for periods when the patients were 
not receiving steroid treatment for the purposes of comparison only. This data is primarily composed 
of insulin sensitivity values from periods after patients had completed glucocorticoid therapy (91% of 
off-steroid hours), so it is potentially biased by improved patient condition and thus may not make a 
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fair comparison with on-steroids hours. In addition, the chosen on/off steroids cut-off point of one 
half-life means that some of this data may still be affected by exogenous glucocorticoids.  
Percentile patient analysis 
Analysis of the percentile patient data also shows a reduction at all likelihoods in insulin sensitivity for 
patients receiving glucocorticoids. Figure 3 shows the CDFs for the 25th, 50th and 75th-percentile 
patients from both cohorts. For all percentile patients, there is a clear difference between those 
receiving steroids and control patients at all likelihood values. Figure 3 shows insulin sensitivity at the 
median likelihood is reduced by 20, 25 and 21% at the 25th, 50th and 75th-percentiles, respectively (p < 
0.001 for all).  
 
Figure 3. CDFs of insulin sensitivity for the 25th, 50th and 75th-percentile patients from the study 
cohorts. 
 
In addition to reductions at the median likelihood, Figure 4 shows the distribution of differences 
between control and steroid percentile patient curves at each likelihood value (y-axis) for all 
17 
 
percentile patients. All distributions are significantly different (indicated on the plot with ‘*’). All 
distributions also have positive median values, indicating consistently reduced insulin sensitivity for 
the steroid percentile patients. Reductions occur across all likelihoods for all but the most extreme 
percentile patients where the highest and lowest values have more variability, sometimes resulting in 
negative differences. This result thus clearly separates the CDFs for each percentile patient.  
 
Figure 4. Differences in insulin sensitivity at all likelihood values between the percentile patients of 
the two cohorts. Significantly different CDFs where p-values < 0.001 in this difference plot are 
indicated with ‘*’.  
 
Simulation and Impact on TGC 
Tables 5 and 6 present the in-silico virtual patient simulation results for the steroid and control 
cohorts. Increasing the insulin sensitivities of steroid cohort patients in simulation by 25 and 43% 
(Table 5) for the periods they received steroids effectively reverses glucocorticoid-mediated 
reductions to SI of 20 to 30% respectively. Similarly, reducing the SI of the control cohort by 20 and 
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30% for 70% of the time they spent on SPRINT simulates the effects of steroid administration on these 
control cohort patients for the proportion of their stay that is comparable to the steroids cohort 
(Table 6). These results show that glucocorticoid-mediated changes in insulin sensitivity have limited 
impact on tight glycaemic control in the ICU setting in the context of the SPRINT protocol.  
 
Median blood glucose levels for both cohorts, and on a per-patient basis, changed by no more than 
7% and remained well within the 4.0-7.0 mmol/L band. Percentage time in the 4.0-7.0 mmol/L band 
(TIB) also changed less than 10%, with no statistically significant differences in the per-patient 
distributions of TIB. As expected, more insulin and fewer carbohydrates were required for reduced SI 
and vice-versa.  
 
Table 5. Simulation results for the steroid cohort. Increasing SI 25-43% to offset the effects of 
glucocorticoid treatment has little impact on clinical interventions and glycaemic control levels. 
 
 
Intervention/metric Ideal (1.0xSI)
Total insulin (U/day) 71.1 64.3 (-9.6%) 61.2 (-14.0%)
Total carbohydrate 
(kcal/day)
343.0 368.5 (+7.4%) 387.9 (+13.1%)
Blood glucose 
(mmol/L)
6.0 
[5.2-7.0]
5.8 
[5.0-6.8]
(-3.8%) 
p<0.001
5.6 
[4.9-6.6]
(-5.9%) 
p<0.001
Time in 4.0-7.0 
mmol/L band (%)
72.3 74.8 (+3.5%) 76.3 (+5.5%)
Total insulin (U/day)
70.5 
[61.5-82.8]
62.7 
[53.7-72.6]
(-11.1%) 
p=0.012
58.7 
[48.1-69.3]
(-13.3%) 
p=0.001
Total carbohydrate 
(kcal/day)
352.8 
[290.7-389.4]
370.7 
[323.8-434.5]
(+5.1%) 
p=0.149
400.2 
[359.3-449.4]
(+13.4%)
 p=0.011
Blood glucose 
(mmol/L)
6.0 
[5.6-6.4]
5.7 
[5.3-6.3]
(-5.0%) 
p=0.109
5.6 
[5.2-6.1]
(-6.1%) 
p=0.013
Time in 4.0-7.0 
mmol/L band (%)
72.1 
[62.3-84.1]
74.8 
[64.4-87.8]
(+3.6%) 
p=0.379
79.2 
[66.6-89.2]
(+9.8%)
 p=0.087
Pe
r-
pa
tie
nt
O
ve
ra
ll 
co
ho
rt
1.25xSI 1.43xSI
19 
 
 
Table 6. Simulation results for the control cohort. Reducing SI 20-30% to simulate the effects of 
glucocorticoid treatment has little impact on clinical interventions and glycaemic control levels. 
 
  
Intervention/metric Ideal (1.0xSI)
Total insulin (U/day) 66.1 71.9 (+8.7%) 74.0 (-12%)
Total carbohydrate 
(kcal/day)
424.8 390.7 (-8.0%) 365.3 (-14.0%)
Blood glucose 
(mmol/L)
5.6 
[5.0-6.6]
5.8 
[5.2-6.8]
(+4.1%) 
p<0.001
6.0 
[5.3-7.0]
(+6.7%) 
p<0.001
Time in 4.0-7.0 
mmol/L band (%)
78.3 75.7 (-3.2%) 74.1 (-5.4%)
Total insulin (U/day)
67.4 
[58.0-77.1]
72.7 
[64.2-80.6]
(+7.9%) 
p=0.107
73.2 
[65.8-82.0]
(+9.8%) 
p=0.049
Total carbohydrate 
(kcal/day)
423.6 
[312.0-478.4]
379.6 
[277.6-428.2]
(-10.4%) 
p=0.073
338.9 
[249.1-406.1]
(-20.0%) 
p=0.004
Blood glucose 
(mmol/L)
5.7 
[5.2-6.2]
5.9 
[5.5-6.3]
(+3.4%) 
p=0.148
5.9 
[5.6-6.4]
(+4.6%) 
p=0.053
Time in 4.0-7.0 
mmol/L band (%)
86.9 
[67.0-89.5]
84.6 
[59.5-89.0]
(-2.6%)
 p=0.389
81.3 
[64.0-87.2]
(-6.5%)
 p=0.075
O
ve
ra
ll 
co
ho
rt
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r-
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tie
nt
0.8xSI 0.7xSI
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Discussion 
Glucocorticoids cause significantly increased insulin resistance (significantly lower insulin sensitivity, 
SI) in healthy individuals [9-13]. The aim of this research was to determine to what extent this effect 
occurs in critically ill patients, who are already relatively insulin resistant due to their condition, and 
how it may affect TGC. The results indicate that there is a reduction in insulin sensitivity in critically ill 
patients associated with the use of glucocorticoids.  
 
In this study, a whole-cohort 31% reduction in median insulin sensitivity was seen between patients 
receiving glucocorticoids (during treatment) and the control cohort. Comparing the insulin 
sensitivities on a percentile patient basis confirms the results seen between cohorts. The median 
percentile patient, representative of a typical patient from the cohort, had a 25% reduction in median 
insulin sensitivity while receiving glucocorticoids. Figure 4 showed that statistically significant 
reductions in insulin sensitivity were associated with glucocorticoid treatment for all percentile 
patients.  
 
Both the percentile patient and cohort analyses point to reductions in insulin sensitivity associated 
with glucocorticoid treatment of 20-30%. These figures are significantly less than the 30-62% 
reductions in insulin sensitivity reported in healthy subjects [9-13]. Differences in steroid dosages are 
unlikely to be responsible for the disparity as the patients in this study received higher equivalent 
daily doses (1.3-4.0 times larger) than the healthy subjects in these previous studies. 
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The dosage and particular drug received by patients in this study varied between individuals and over 
the course of treatment. However, over the entire cohort the median daily dose of glucocorticoid was 
equivalent to 200 mg/d (IQR: 80-200 mg/d) of hydrocortisone per patient. In contrast, subjects in the 
previous studies  [9-10, 12-13] were either administered 2 mg/d of dexamethasone, equivalent to 50 
mg/d of hydrocortisone [9-10, 12], or 15 mg/d of prednisone, equivalent to 60 mg/d of 
hydrocortisone [13]. Larsson and Ahren [11] reported a 54% reduction with 6 mg/d dexamethasone 
(equivalent to 150 mg/d hydrocortisone). Hence, the results of this study show lower reductions in 
insulin sensitivity compared to studies on healthy individuals, despite glucocorticoid doses that are 
1.3-4.0 times larger. This result indicates a significantly reduced impact of glucocorticoids on insulin 
sensitivity in the critically ill. 
 
The results of this study also reveal the potential impact of glucocorticoids on TGC under the SPRINT 
protocol. Virtual patient simulations show that the SPRINT protocol can manage these changes in SI by 
modulating the insulin and nutrition inputs by up to 20%, while maintaining tight glycaemic control. 
Hence, reductions in insulin sensitivity of 20-30% associated with glucocorticoid treatment in the ICU 
have limited impact on the quality of TGC, at least within the context of the SPRINT protocol.  
Physiological Rationale and Possible Causes 
Although much research has been conducted on the effects of glucocorticoids on insulin sensitivity, 
very little is known about the specific mechanisms of action. Glucocorticoids reduce insulin sensitivity 
directly, as well as disrupting glucose metabolism at the liver, pancreas and peripheral tissues. Several 
studies have indicated that decreased cellular glucose uptake is at least partly responsible [13, 32-33]. 
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Impaired intracellular glucose oxidation has also been shown to have a role in glucocorticoid induced 
insulin resistance [32-33]. In addition, endogenous glucose production is enhanced by glucocorticoids 
[9, 12-13, 34], possibly through their enhancement of the synthesis and action of catecholamines [19, 
32, 35-36]. 
 
Delaunay et al. [37] and Lambillotte et al. [38] showed that glucocorticoids suppress insulin secretion 
through a direct action on the pancreatic β-cells. However, the results from Binnert et al. [9], Besse et 
al. [34] and Nicod et al. [12] show a clear increase in glucose-induced insulin secretion after 
administration of dexamethasone. It is possible that there are competing pathways with the net 
effect depending upon specific physiological conditions.  
 
In summary, critically ill patients have elevated levels of circulating cortisol and catecholamines due to 
their stress response [4, 39]. Any increase or enhancement of their action may have a reduced effect 
due to saturation of the physiological impact of these agents. For example, the increased hepatic 
glucose production associated with glucocorticoids may be blunted as it is already significantly 
enhanced due to the patients’ condition. Healthy individuals, in contrast, typically have much lower 
levels of circulating catecholamines and cortisol. They would therefore show more significant 
reductions in SI and increases in EGP with additional, exogenous glucocorticoids than critically ill 
patients.  
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Limitations 
A major limitation of using model-based methods is that the parameter of interest (SI) is not 
measured directly and may be influenced by modelling errors or un-modelled effects. The insulin 
sensitivity parameter in the model used for this research captures the relative net effect of altered 
EGP, peripheral and hepatic insulin mediated glucose uptake and endogenous insulin secretion. 
Therefore, increased EGP, reduced insulin mediated glucose uptake or reduced insulin secretion result 
in a decrease in effective SI captured by this model. Hence, glucocorticoid mediated changes to 
glucose metabolism, in addition to the direct effect on insulin sensitivity, cause a relative reduction in 
the model-based SI. While this model-based SI represents more of a “whole-body” insulin sensitivity, it 
still correlates very well (r > 0.90) with euglycaemic clamp derived insulin sensitivity, ISI [24], providing 
support for this metric and overall analysis. 
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Conclusions 
This research used model-based methods to show that glucocorticoids cause less of a reduction in the 
insulin sensitivity of critically ill patients than in healthy individuals. Both the percentile patient and 
cohort analyses point to reductions in insulin sensitivity associated with glucocorticoid treatment of 
20-30%. These results are typically less than the 30-62% reductions in insulin sensitivity reported in 
healthy subjects, despite equivalent glucocorticoid doses in this study 1.3-4 times larger. This reduced 
suppression of insulin sensitivity in critically ill patients could be a result of saturation of the 
physiological impact of glucocorticoids due to already increased levels of catecholamines and cortisol 
common in critically illness. Virtual trial simulations showed that reductions in insulin sensitivity of 20-
30% associated with glucocorticoid treatment in the ICU have limited impact on TGC, at least within 
the context of the SPRINT protocol. 
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